Future Family

Future Family is a San Francisco-based fertility financing company that provides payment plans, insurance products and care support for people undergoing in vitro fertilization (IVF), egg freezing and related treatments. Customers can apply for up to $50,000 in financing, with prequalification described as taking minutes and having no impact on credit, and funding available within 24 hours. Its IVF payment plan starts at $300 per month and covers clinic procedures, lab work and medications, while an egg-freezing plan starts at $150 per month and also includes storage.

Alongside lending, the company operates a clinic-matching tool for comparing providers, treatments and pricing; a dedicated fertility nurse coaching service providing one-on-one virtual support and personalized treatment plans; and Future Family Rx, an online fertility pharmacy platform launched in May 2024 to simplify medication management for providers and patients, offered in partnership with fertility pharmacies. In February the company introduced Orange Shield, an insurance product with refund levels of $15,000 for a single cycle, $30,000 for two cycles and $50,000 for two cycles with medication coverage, priced on average at $3,000 down plus $999 per month for five months. Orange Shield plans carry a "Baby or Your Money Back" guarantee under which patients whose IVF cycles are unsuccessful after two cycles can file a claim for a refund. Building the insurance product took 18 months and required constructing an actuarial model and securing reinsurance capacity.

The company has also built membership products for specific patient groups, including a reciprocal IVF membership plan for lesbian and trans couples announced in January 2020 and a Trying-to-Conceive (TTC) membership plan. The reciprocal IVF plan was priced at a one-time fee of $499 promotionally in January 2020 and $898 thereafter, including a dedicated fertility coach, fertility testing for both partners, sperm bank matching and medication discounts, with optional payment plans layered on top.

Founding story

Founder and CEO Claire Tomkins holds a PhD in applied economics and finance from Stanford University and worked in consumer finance before founding the company. She started Future Family after her own experience with the confusion, complexity and high cost of IVF; she is now a mother of three children conceived through IVF. Her thesis was that family building via IVF needed a dedicated financial product, comparable to mortgages, auto loans or education loans.

Business model

Future Family combines consumer lending with insurance and care services for fertility patients. It underwrites multi-disbursement financing that pays clinics and pharmacies directly on behalf of patients, sells monthly payment plans for IVF and egg freezing, sells membership plans that bundle coaching, testing and discounts, and sells the Orange Shield refund-based insurance product. Lending capacity is supported by external capital, including a $400 million financing program from Clear Haven Capital Management announced in April.

Revenue derives from fertility financing (monthly payment plans starting at $300 per month for IVF and $150 per month for egg freezing), insurance premiums for Orange Shield (approximately $3,000 down plus $999 per month for five months on average), one-time membership fees such as the $499/$898 reciprocal IVF plan, and fertility pharmacy services through Future Family Rx.

Traction

The company reports more than $200 million in credit extended to U.S. families, more than 10,000 patients served, over 600 partner clinics, and a 4.8 rating on Trustpilot. It states it has raised $48 million in venture capital and secured a $400 million financing program from Clear Haven Capital Management.

Latest developments

The Orange Shield nationwide IVF insurance product launched in February with three refund tiers and a "Baby or Your Money Back" guarantee, and on April 3 the company announced a $400 million financing program from Clear Haven Capital Management to expand its lending platform. Cumulative figures cited include $48 million raised in venture capital, more than $200 million in credit extended and over 10,000 patients served.